|
|||||
|
|
Pharmacodynamics,pharmacokinetics and safety of multiple ascending doses of the novel dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 agonist RG7697 in people with type 2 diabetes mellitus |
|
| Authors: | Christophe Schmitt PharmD Agnès Portron PharmD Shirin Jadidi MD Neena Sarkar PhD Richard DiMarchi PhD |
| Affiliation: | 1. Department of Clinical Pharmacology, F. Hoffmann‐La Roche AG, Basel, Switzerland;2. Department of Safety Science, Roche Innovation Center, New York, New York;3. Department of Biostatistics, Roche Innovation Center, New York, New York;4. Department of Chemistry, Novo Nordisk Research Center Indianapolis, Indianapolis, Indiana |
| Abstract: | |
| Keywords: | dual GIP/GLP‐1 agonist NNC0090‐2746 pharmacodynamics pharmacokinetics RG7697, RO6811135 safety type 2 diabetes mellitus |